文献速递技术与安全腹部胸部CT

CT衍生的身体成分评估作为肿瘤患者的预后工具:从机会性研究到基于人工智能的临床实施

CT-Derived Body Composition Assessment as a Prognostic Tool in Oncologic Patients: From Opportunistic Research to Artificial Intelligence-Based Clinical Implementation.
PubMed 文献 · AJR Am J Roentgenol · 2022-06-01

CT身体成分测量在研究中已确立为肿瘤患者的预后标志物,多项回顾性研究显示腹部CT提取的骨骼肌、腹部脂肪和骨密度指标比传统临床方法更准确评估衰弱和癌症恶病质。肝脏脂肪和主动脉粥样硬化钙化的定量CT测量也提供预后信息。人工智能全自动分割工具有望将这些机会性测量从研究转化至临床实践,用于更精准的风险分层。

要点

  • 腹部CT可机会性测量骨骼肌、腹部脂肪和骨密度,比传统方法更准确评估衰弱和癌症恶病质。
  • 肝脏脂肪和主动脉粥样硬化钙化的定量CT也提供预后信息,但在肿瘤诊疗中关注较少。
  • 人工智能全自动分割工具有望替代人工方法,推动身体成分评估进入临床实践。

核心结论

  • CT身体成分测量在肿瘤患者中具有预后价值,人工智能自动化工具可推动其从研究转化为临床实践,用于精准风险分层。

研究设计与样本

  • 综述性文章,总结CT身体成分评估在肿瘤患者中的研究进展与临床转化前景,未报告具体样本量或中心数。

关键影像表现/征象

  • 腹部CT图像可提取骨骼肌、腹部脂肪和骨密度的客观测量值,用于评估衰弱和癌症恶病质。
  • 肝脏脂肪和主动脉粥样硬化钙化的定量CT测量也可提供预后信息。

临床应用与阅片要点

  • 肿瘤患者常规进行系列CT检查用于分期、疗效评估和监测,为机会性身体成分评估提供了条件。
  • 全自动人工智能分割与定量工具有望替代耗时的人工和半自动方法,推动身体成分分析进入临床实践。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

CT-based body composition measures are well established in research settings as prognostic markers in oncologic patients. Numerous retrospective studies have shown the role of objective measurements extracted from abdominal CT images of skeletal muscle, abdominal fat, and bone mineral density in providing more accurate assessments of frailty and cancer cachexia in comparison with traditional clinical methods. Quantitative CT-based measurements of liver fat and aortic atherosclerotic calcification have received relatively less attention in cancer care but also provide prognostic information. Patients with cancer routinely undergo serial CT examinations for staging, treatment response, and surveillance, providing the opportunity for quantitative body composition assessment to be performed as part of routine clinical care. The emergence of fully automated artificial intelligence-based segmentation and quantification tools to replace earlier time-consuming manual and semiautomated methods for body composition analysis will allow these opportunistic measures to transition from the research realm to clinical practice. With continued investigation, the measurements may ultimately be applied to achieve more precise risk stratification as a component of personalized oncologic care.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Bates, Pickhardt. CT-Derived Body Composition Assessment as a Prognostic Tool in Oncologic Patients: From Opportunistic Research to Artificial Intelligence-Based Clinical Implementation. AJR Am J Roentgenol. 2022. PMID: 35642760. doi:10.2214/AJR.22.27749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。